Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Prostate Cancer and Prostatic Diseases|August 27, 2021
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223Sushil K Badrising, Rebecca D Louhanepessy, Vincent van der Noort, et al.Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.European Urology Oncology|October 1, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA AnalysisKaran Parekh, Kim van der Zande, Sarah W S Ng, et al.Journal of the National Cancer Institute|November 21, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trialNoor Wortelboer, Seamus Kent, Hedwig M Blommestein, et al.British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.Nature|November 28, 2024
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancerGabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, et al.Drugs - Real World Outcomes|May 9, 2026
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerDianne Bosch, Kim J M van der Velden, Aart Beeker, et al.The Lancet. Haematology|December 3, 2025
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trialArnon P Kater, Sabina Kersting, Julie M Dubois, et al.JNCI Cancer Spectrum|January 27, 2026
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES studyAniek Bonhof, Anouk E Hiensch, Nicolette J Wierdsma, et al.Pageof 5